TUDELs

Meet TUDELs.

TUDELs transforms early-stage drug discovery by integrating complementary screening methods with machine learning for faster, smarter and more accessible drug discovery.

The Team

  •  Dr Ian Hope (Lead): Expert in medicinal chemistry, FBDD, DEL and structural biology; led 3 oncology-targeted fragment screening campaigns and contributed to 2 pharma patents.
  • Dr Kevin Bevernaege: Synthetic and medicinal chemist (5+ years) with valued skills in algorithm development (10+ years) and DEL data deconvolution.
  • Prof Mike Waring: Head of Medicinal Chemistry and director of MoSMed at Newcastle University, former AstraZeneca Principal Scientist and co-discoverer of Osimertinib, bringing over 25 years of strategic expertise in hit identification and translational medicinal chemistry.
  • Dr Harriet Stanway-Gordon: 1851 Fellow and expert in DEL methodology, design and validation. Co-creator and curator of Faces of Science.
logo

Problem

Individuals battling severe, life-changing diseases need fast access to effective therapies, yet the development of new treatments remains slow, inefficient and constrained by siloed workflows. Critical bottlenecks in early-stage drug discovery, often relying on a trial-and-error approach, delay promising therapies from reaching patients, leaving urgent medical needs unmet and limiting the potential of innovative medicines

Solution

TUDELs (Targeted, Unified DNA-Encoded Libraries) is a structure-guided drug discovery platform that unifies fragment-based drug discovery and DNA-encoded libraries into a single, automated workflow powered by machine learning. By integrating these complementary methods, TUDELs accelerates the identification of promising drug candidates, shortens development timelines and enables exploration of previously intractable drug targets. Our platform delivers more reliable drug candidates, rapidly transforming and advancing early-stage drug discovery programs and bringing effective therapies to patients faster.

Contact

Ian Hope LinkedIn

Harriet Stanway-Gordon

This article was published on